| HOME >> MEDICINE >> TECHNOLOGY |
Below is a reconciliation of GAAP net earnings attributable to Mylan Inc. to adjusted EBITDA for the three and nine months ended September 30, 2010, and 2009 (in millions): Three months ended September 30,Nine months ended September 30,2010200920102009GAAP net earnings (loss) attributable to Mylan Inc. before preferred dividends
$ 143.2$ (5.2)$
325.3$ 193.7Add/(Deduct):Net contribution attributable to the noncontrolling interest and equity method investees
0.40.9(0.6)5.5Income taxes
(12.0)(11.1)33.352.5Interest expense
87.577.0240.0240.2Depreciation and amortization
108.0103.5312.9299.2EBITDA
$ 327.1$ 165.1$
910.9$ 791.1Add Adjustments:Stock-based compensation expense
8.58.924.123.6Litigation settlements, net
1.5114.314.3111.5Integration and other special items
31.012.176.515.9Adjusted EBITDA
$ 368.1$ 300.4$ 1,025.8$ 942.1Conference CallMylan will host a conference call and live webcast today, Tuesday, October 26, 2010, at 5:00 p.m. ET, in conjunction with the release of its financial results. The dial-in number to access the call is 888.298.3511, or 719.457.2710 for international callers. A replay, available for approximately seven days, can be accessed by calling 888.203.1112 or 719.457.0820 for international callers, pass code 1214329. To access a live webcast of the call, and the accompanying presentation, please log on to Mylan's website (www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on www.mylan.com for approximately seven days.
About MylanMylan Inc. ranks among the leading generic and specialty pharmaceutical compan
'/>"/>
| SOURCE Mylan Inc. Copyright©2010 PR Newswire. All rights reserved |